Choose Adult IndicationDrugDrug name X NVAF Reduce stroke risk PAD Reduce the risk of major thrombotic vascular events CAD Reduce the risk of major CV events VTE Prophylaxis Acutely Ill Medical Patients DVT/PE Initial treatment DVT/PE Extended treatment DVT Prophylaxis After hip/knee replacement surgery Home Clinical Trial Efficacy Profile Safety Profile Dosing Home Clinical Trials Efficacy Safety Net Clinical Benefit Summary Dosing Home Clinical Trials Efficacy Profile Safety Profile Dosing Home Clinical Trials Efficacy Profile Safety Profile Dosing Home Clinical Trial Efficacy Profile Safety Profile Dosing Home Clinical Trials Efficacy Profile Safety Profile Dosing Home Clinical Trial Efficacy Profile Safety Profile Dosing Adult Dosing NVAF CAD/PAD DVT/PE Adult Switch and Management Switching to/from XARELTO® Bleed management considerations Temporary discontinuation Other administration Access and Support Janssen Select Janssen CarePath Formulary Finder Prescription Assistance Request XARELTO® samples Resources Resources Hub FAQs Pediatric VTE (Pediatrics) Post Fontan (Pediatrics) Search Important Safety Information US Prescribing Information Medication Guide For Non-US Visitors Patient Site SEARCH For Choose Adult Indication NVAFReduce stroke risk PADReduce the risk of major thrombotic vascular events CADReduce the risk of major CV events VTE ProphylaxisAcutely Ill Medical Patients DVT/PEInitial treatment DVT/PEExtended treatment DVT ProphylaxisAfter hip/knee replacement surgery
